AnalystsBrian AbrahamsBrian Abrahams's Stock Forecasts
AnalystsBrian Abrahams
Sectors:
Industries:
Analyst Ranking
Top 2%
#51 out of 4174 analysts
Average Return
+25.05%
Win Rate
65%48 out of 74
Risk vs Reward
Poor
Good
Brian Abrahams's 5 best and worst ratings
| Name / Ticker | Gain/Loss | Entry Price | Exit Price | Period | Rating |
|---|---|---|---|---|---|
Pliant Therapeutics IncPLRX | +614.88% | $4.67 | $33.39 | 2022-05-09 - 2023-02-03 | Buy |
89bio IncETNB | +395.88% | $2.67 | $13.24 | 2022-05-11 - 2023-02-03 | Buy |
Sage Therapeutics IncSAGE | +206.50% | $28.00 | $85.82 | 2020-03-17 - 2021-01-04 | Buy |
Sage Therapeutics IncSAGE | +185.97% | $30.01 | $85.82 | 2020-04-07 - 2021-01-04 | Buy |
Sage Therapeutics IncSAGE | +137.92% | $62.36 | $148.37 | 2017-09-14 - 2018-09-14 | Buy |
Brian Abrahams Analyst Color
Get additional color on Brian Abrahams's coverage of popular stocks
Brian Abrahams's Stock Coverage
| Name / Ticker | No. Ratings | Rating | Price Target | Upside/Downside | Action | Date |
|---|---|---|---|---|---|---|
Xenon Pharmaceuticals IncXENE | 6 | Buy | $51.00 | +30.14% | Maintains | 7 days ago |
Marinus Pharmaceuticals IncMRNS | 1 | Buy | $23.00 | +252.22% | Initiates Coverage On | 18 days ago |
Gilead Sciences IncGILD | 9 | Hold | $87.00 | +2.96% | Downgrades | a month ago |
Enanta Pharmaceuticals IncENTA | 10 | Hold | $54.00 | +2.86% | Maintains | 3 months ago |
Mind Medicine IncMNMD | 1 | Buy | $5.00 | +44.51% | Initiates Coverage On | 3 months ago |
Hookipa Pharma IncHOOK | 3 | Buy | $7.00 | +600.00% | Maintains | 3 months ago |
89bio IncETNB | 3 | Buy | $29.00 | +119.03% | Maintains | 3 months ago |
Pliant Therapeutics IncPLRX | 3 | Buy | $50.00 | +49.77% | Maintains | 3 months ago |
Galapagos NvGLPG | 7 | Hold | $53.00 | +24.94% | Maintains | 3 months ago |
Igm Biosciences IncIGMS | 4 | Hold | $22.00 | -8.33% | Maintains | 3 months ago |
Prothena Corp Public Ltd CoPRTA | 3 | Hold | $55.00 | -4.76% | Downgrades | 3 months ago |
Karyopharm Therapeutics IncKPTI | 4 | Buy | $10.00 | +194.12% | Upgrades | 3 months ago |
Sarepta Therapeutics IncSRPT | 6 | Buy | $190.00 | +59.66% | Maintains | 3 months ago |
Neurocrine Biosciences IncNBIX | 3 | Hold | $117.00 | +6.33% | Maintains | 3 months ago |
Incyte CorpINCY | 5 | Buy | $82.00 | -1.93% | Maintains | 3 months ago |
Biocryst Pharmaceuticals IncBCRX | 4 | Hold | $13.00 | +23.22% | Maintains | 3 months ago |
Vertex Pharmaceuticals IncVRTX | 8 | Hold | $288.00 | -4.33% | Maintains | 3 months ago |
Ptc Therapeutics IncPTCT | 7 | Hold | $46.00 | -4.25% | Maintains | 3 months ago |
Biogen IncBIIB | 13 | Buy | $331.00 | +16.70% | Maintains | 3 months ago |
Karuna Therapeutics IncKRTX | 4 | Buy | $293.00 | +52.61% | Maintains | 4 months ago |
Intra Cellular Therapies IncITCI | 5 | Buy | $70.00 | +43.09% | Maintains | 6 months ago |
Intercept Pharmaceuticals IncICPT | 5 | Hold | $18.00 | -5.36% | Maintains | 9 months ago |
Regeneron Pharmaceuticals IncREGN | 2 | Hold | $658.00 | -15.98% | Maintains | 9 months ago |
Sage Therapeutics IncSAGE | 8 | Hold | $35.00 | -20.74% | Maintains | 9 months ago |
Atai Life Sciences NvATAI | 3 | Hold | $9.00 | +381.28% | Maintains | 10 months ago |
Merus NvMRUS | 3 | Hold | $33.00 | N/A | Maintains | a year ago |
Constellation Pharmaceuticals IncCNST | 1 | Hold | $34.00 | N/A | Downgrades | 2 years ago |
Metacrine IncMTCR | 1 | Buy | $25.00 | N/A | Initiates Coverage On | 2 years ago |
Corbus Pharmaceuticals Holdings IncCRBP | 1 | Hold | N/A | N/A | Downgrades | 2 years ago |
Neubase Therapeutics IncNBSE | 1 | Buy | $16.00 | N/A | Initiates Coverage On | 3 years ago |
Celgene CorpCELG | 2 | Buy | $118.00 | N/A | Downgrades | 5 years ago |
Ultragenyx Pharmaceutical IncRARE | 2 | Strong Buy | N/A | N/A | Upgrades | 5 years ago |
Epizyme IncEPZM | 1 | Hold | N/A | N/A | Downgrades | 5 years ago |
Alder Biopharmaceuticals IncALDR | 1 | Buy | $17.00 | N/A | Initiates Coverage On | 5 years ago |
Immune Design CorpIMDZ | 1 | Buy | $20.00 | N/A | Initiates Coverage On | 5 years ago |
Avexis IncAVXS | 1 | Hold | $92.00 | N/A | Initiates Coverage On | 5 years ago |
©2023 WallStreetZen
Company
AboutBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.